Studies of SARS virus vaccines.
1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
Zheng
B J
BJ
Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong.
Du
L Y
LY
Zhao
G Y
GY
Lin
Y P
YP
Sui
H Y
HY
Chan
C
C
Ma
S
S
Guan
Y
Y
Yuen
K Y
KY
D000281:Administration, Intranasal; D000818:Animals; D003140:Communicable Disease Control; D004195:Disease Models, Animal; D004196:Disease Outbreaks / Q000517:prevention & control; D005260:Female; D005544:Forecasting; D006723:Hong Kong; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D051379:Mice; D011237:Predictive Value of Tests; D018570:Risk Assessment; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000706:statistics & numerical data*; D015164:Vaccines, Inactivated / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology
D015164:Vaccines, Inactivated; D014765:Viral Vaccines